Stay updated on Risankizumab vs Secukinumab in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Risankizumab vs Secukinumab in Psoriasis Clinical Trial page.

Latest updates to the Risankizumab vs Secukinumab in Psoriasis Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page now includes a government funding notice about potential data/tansaction delays and states the NIH Clinical Center is open, along with a new software version (v3.2.0) replacing v3.1.0.SummaryDifference3%
- Check21 days agoChange DetectedUpdated version from v3.0.2 to v3.1.0, indicating a new release. No other content changes were detected.SummaryDifference0.1%
- Check28 days agoNo Change Detected
- Check36 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2. The 'Back to Top' element was removed.SummaryDifference0.2%
- Check43 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.2%
- Check50 days agoChange DetectedThe webpage has undergone significant updates, including the addition of new facility names and locations across various countries, while also removing several previously listed locations. Notably, the drug names 'risankizumab' and 'secukinumab' have been retained in the content.SummaryDifference6%
- Check64 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to Risankizumab vs Secukinumab in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risankizumab vs Secukinumab in Psoriasis Clinical Trial page.